NRX Pharmaceuticals Inc (NRXP)

NASDAQ
Currency in USD
2.630
-0.150(-5.40%)
Closed·
After Hours
2.580-0.050(-1.901%)
·
NRXP Scorecard
Full Analysis
RSI suggests the stock is in overbought territory
Unusual trading volume
Fair Value
Day's Range
2.4703.000
52 wk Range
1.1006.010
Key Statistics
Edit
Prev. Close
2.78
Open
2.84
Day's Range
2.47-3
52 wk Range
1.1-6.01
Volume
1.33M
Average Vol. (3m)
226.05K
1-Year Change
-31.53%
Book Value / Share
-1.49
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
NRXP Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
28.500
Upside
+983.65%
Members' Sentiments
Bearish
Bullish
ProTips
Significant return over the last week
Show more

NRX Pharmaceuticals Inc Company Profile

NRx Pharmaceuticals, Inc., a clinical-stage bio-pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders comprising suicidal depression, post-traumatic stress disorder, and chronic pain. Its lead drug candidates include NRX-101, an oral, fixed dosed combination of D-cycloserine and lurasidone for suicidal treatment-resistant bipolar depression in patients with sub-acute suicidal ideation and behavior in phase 2 trial; and NRX-100, a preservative-free formulation of ketamine for intravenous infusion and for the treatment of suicidal depression. The company has a license agreement with Alvogen, Inc. and Lotus Pharmaceutical Co. Ltd.; Apkarian Technologies; development and license agreement with Glytech, LLC; and Sarah Herzog Memorial Hospital. NRx Pharmaceuticals, Inc. was founded in 2015 and is based in Wilmington, Delaware.

NRX Pharmaceuticals Inc Earnings Call Summary for Q1/2025

  • Net loss reduced to $5.5M in Q1 2025 from $6.5M in Q1 2024; company targets profitability by end of 2025
  • NDA filed for NRx100 (ketamine-based treatment); FDA approvals for NRx100 and NRx101 expected in 2025
  • Plans to expand clinic network and explore international markets; revenue from clinic operations anticipated before year-end
  • Stock rose 5.73% in regular trading, fell 2.85% after hours; analyst price targets range from $18 to $46
  • Cash and equivalents at $5.5M; InvestingPro notes weak margins and short-term obligations exceeding liquid assets
Last Updated: 05/15/2025, 05:29 PM
Read Full Transcript

Compare NRXP to Peers and Sector

Metrics to compare
NRXP
Peers
Sector
Relationship
P/E Ratio
−1.8x−0.5x−0.5x
PEG Ratio
−0.05−0.010.00
Price / Book
−1.8x−0.1x2.6x
Price / LTM Sales
-1.8x3.0x
Upside (Analyst Target)
-264.7%52.7%
Fair Value Upside
Unlock9.3%7.6%Unlock

Analyst Ratings

4 Buy
0 Hold
0 Sell
Ratings:
4 analysts
Overall Consensus
Strong Buy

Analysts 12-Month Price Target:

Average 28.500
(+983.65% Upside)

Earnings

Latest Release
Mar 14, 2025
EPS / Forecast
-0.74 / -0.08
Revenue / Forecast
-- / --
EPS Revisions
Last 90 days

People Also Watch

3.110
KPRX
-1.58%
4.0100
ATHE
-4.52%
2.150
MEIP
+4.88%

FAQ

What Is the NRX Pharmaceuticals (NRXP) Stock Price Today?

The NRX Pharmaceuticals stock price today is 2.63

What Stock Exchange Does NRX Pharmaceuticals Trade On?

NRX Pharmaceuticals is listed and trades on the Nasdaq Stock Exchange stock exchange.

What Is the Stock Symbol for NRX Pharmaceuticals?

The stock symbol for NRX Pharmaceuticals is "NRXP."

What Is the NRX Pharmaceuticals Market Cap?

As of today, NRX Pharmaceuticals market cap is 44.66M.

What Is NRX Pharmaceuticals's Earnings Per Share (TTM)?

The NRX Pharmaceuticals EPS (TTM) is -1.92.

From a Technical Analysis Perspective, Is NRXP a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.

How Many Times Has NRX Pharmaceuticals Stock Split?

NRX Pharmaceuticals has split 1 times.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2025 - Fusion Media Limited. All Rights Reserved.